"The Evaluation of Stimulant Withdrawal"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-01

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cocaine Withdrawal and Pharmacotherapy Response

NCT00566969

Cocaine Dependence Opiate Dependence

COMPLETED NA

Studying Amphetamine Withdrawal in Humans

NCT01215929

Methamphetamine Dependence

COMPLETED PHASE2

Methylphenidate to Treat Methamphetamine Dependence

NCT01044238

Methamphetamine Dependence

UNKNOWN PHASE2

Tyrosine for Methamphetamine Dependence - 1

NCT00000322

Amphetamine-Related Disorders

COMPLETED PHASE2

A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1

NCT00033124

Substance-Related Disorders

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety Relapse Substance Addiction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTRL

Group Type PLACEBO_COMPARATOR

Coreg

Intervention Type DRUG

TREAT

Group Type EXPERIMENTAL

Coreg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coreg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
* Must meet the clinical definition for methamphetamine dependence
* Self-reported methamphetamine use within 10 days of entering the study
* Must be able to understand and sign the consent form

Exclusion Criteria

* Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
* Pregnant or nursing mothers
* Psychosis
* Dementia
* Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
* History of withdrawal seizures or delirium tremors
* Use of MAO inhibitors within the last two weeks
* Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes